Effects of ZA and IL-2 on NK cells
There was no difference observed in median NK cell frequency over time in patients treated with zolbetuximab + ZA and intermediate-dose or low-dose IL-2 versus those treated with zolbetuximab alone (Table Kinetic profile of activated CD69